Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2025)

Catalyst Pharmaceuticals' Finished Goods history spans 3 years, with the latest figure at $16.2 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 68.7% year-over-year to $16.2 million; the TTM value through Dec 2025 reached $16.2 million, up 68.7%, while the annual FY2025 figure was $16.2 million, 68.7% up from the prior year.
  • Finished Goods reached $16.2 million in Q4 2025 per CPRX's latest filing, up from $11.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $16.2 million in Q4 2025 to a low of $8.1 million in Q1 2025.
  • Average Finished Goods over 3 years is $10.0 million, with a median of $9.2 million recorded in 2023.
  • The largest YoY upside for Finished Goods was 68.7% in 2025 against a maximum downside of 3.29% in 2025.
  • A 3-year view of Finished Goods shows it stood at $9.2 million in 2023, then rose by 4.55% to $9.6 million in 2024, then surged by 68.7% to $16.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Finished Goods are $16.2 million (Q4 2025), $11.3 million (Q3 2025), and $8.1 million (Q2 2025).